BioSight
Companies
EyePoint, Inc. logo

EYPT

NASDAQWATERTOWN, MA
EyePoint, Inc.

EyePoint develops sustained-delivery eye treatments for retinal diseases, with its lead candidate DURAVYU being an investigational intravitreal insert containing vorolanib (a tyrosine kinase inhibitor) aimed at wet age-related macular degeneration and diabetic macular edema. The pipeline also includes EYP-2301, a TIE-2 agonist formulated in a sustained-release insert for serious retinal diseases. DURAVYU is in Phase 3 clinical development with topline data expected in 2026.

Price history not yet available for EYPT.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar